Topics

CAR-T Therapy Challenges: Tumor Relapse

Cancer Immunotherapy Cellular Stress Cell Programmed Death Tumor Microenvironment

Tumor relapse is the principal limit on the curative potential of CAR-T therapy. A patient may never achieve a deep response, recur soon after initial clearance, or relapse after a prolonged remission, and those patterns can reflect different biology. Resistance is commonly divided into antigen-positive relapse, in which target remains but CAR-T cells are insufficient, and antigen-negative relapse, in which tumor recognition has been lost. This distinction emerged prominently with CD19-directed therapy and now guides post-relapse biopsy and treatment selection. Modern research treats relapse as an evolving interaction among tumor genotype and phenotype, CAR design, manufactured T-cell quality, host immunity, and the tissue microenvironment rather than as a single defect Relapse timing can provide an initial clue, because immediate progression and recurrence after long cellular persistence rarely have identical causes[1][2][3].

Antigen-negative escape can arise through mutation, altered splicing, reduced surface density, lineage change, or selection of a pre-existing antigen-low clone. Trogocytosis may transfer target molecules to CAR-T cells, simultaneously lowering tumor antigen and provoking fratricide or exhaustion. Antigen-positive relapse instead points toward limited expansion, poor persistence, tonic receptor signaling, terminal differentiation, checkpoint inhibition, defective cytotoxic signaling, or resistance of tumor cells to apoptosis. High tumor burden and inflammatory stress can accelerate dysfunction. In solid tumors, trafficking and metabolic suppression add further barriers; in marrow and lymphoid tissue, stromal and myeloid signals also shape persistence. The same patient can harbor more than one mechanism, so a binary antigen test is necessary but not sufficient Host anti-CAR immunity can add another layer by accelerating clearance of cells that express immunogenic receptor components[1][2].

Clinical management should reassess target expression, disease distribution, tempo, and prior CAR kinetics whenever tissue is safely obtainable. If the original antigen persists, options may include a second cell product, a different construct, bispecific antibody therapy, targeted drugs, or transplantation in selected settings. Antigen-negative disease requires a new target such as CD20 or CD22 rather than simple re-exposure to the same receptor. Multispecific CARs, sequential targeting, and tandem receptors aim to prevent escape before it occurs. Improving manufacturing from less differentiated T cells, adjusting costimulation, reducing tonic signaling, or adding checkpoint resistance may address cell-intrinsic failure. Rescue choices must also consider prolonged cytopenia, infection risk, and the patient’s ability to undergo another intensive therapy Rapid access to validated antigen testing is therefore part of treatment infrastructure, not merely a research convenience after failure[1][3].

The major research gap is the lack of standardized, longitudinal relapse profiling. Trials should pair baseline tumor material with samples after infusion and at progression, while measuring antigen density, CAR expansion, phenotype, clonality, cytokines, and tumor death pathways. Circulating tumor DNA may reveal emerging relapse earlier, but tissue remains important for identifying antigen and lineage. Preventive engineering should be matched to observed risk: dual targeting for heterogeneous antigen, memory-preserving production for poor persistence, and microenvironmental combinations for localized suppression. More potent cells are not automatically more durable or safer. The goal is a controllable immune population that maintains surveillance as tumor cells adapt, supported by a relapse taxonomy that directs rational salvage instead of empiric sequencing Shared definitions of antigen loss, persistence failure, and lineage change would also make resistance studies more comparable across products[1][2][3].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-11109 Resatorvid
Resatorvid (TAK-242) is a selective Toll-like receptor 4 (TLR4) inhibitor. Resatorvid inhibits NO, TNF-α and IL-6 production with IC50s of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF. Resatorvid inhibits autophagy and plays pivotal role in various inflammatory diseases.
Toll-like Receptor (TLR)   TNF Receptor   Interleukin Related   Autophagy  
Prostate Cancer   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
524
HY-100573 Necrosulfonamide
Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
Mixed Lineage Kinase   Necroptosis   Pyroptosis   Caspase   NOD-like Receptor (NLR)   Keap1-Nrf2   TNF Receptor   Interleukin Related   NO Synthase   Heme Oxygenase (HO)  
Digestive System Disease   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Depression   Digestive System Inflammation   Cardiovascular Disease   Parkinson's Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
144
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 813 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-L260 KRAS Targeted Compound Library
KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) is one of the most important oncogenic driver genes in oncology, with high mutation frequencies in pancreatic cancer, non‑small cell lung cancer, and colorectal cancer. For a long time, KRAS was considered "undruggable" due to the lack of suitable small‑molecule binding pockets on its protein surface. In recent years, with the discovery of the switch‑II pocket and the successful approval of KRAS G12C inhibitors, KRAS‑targeted research has achieved groundbreaking progress, which has also spurred a wave of development targeting non‑G12C mutants such as G12D and G12V, as well as upstream and downstream regulatory factors including SOS1 and SHP2. MCE KRAS Targeted Compound Library contains 79 small‑molecule compounds targeting the KRAS, serving as high‑quality research tools for mechanistic studies of KRAS‑mutant tumors, combination therapy development, resistance mechanism exploration, and high‑throughput drug screening, thereby providing robust support for KRAS‑targeted drug discovery.

Signaling Pathway Targeting Libraries

83
HY-16141 Cilengitide
Cilengitide (EMD 121974) is a BBB-permeable integrins antagonist with IC50s of 0.61 nM (ανβ3), 8.4 nM (ανβ5) and 14.9 nM (α5β1), respectively. Cilengitide inhibits the binding of ανβ3 and ανβ5 to Vitronectin with IC50s of 4 nM and 79 nM, respectively. Cilengitide inhibits TGF-β/Smad signaling, mediates PD-L1 expression. Cilengitide also induces apoptosis, shows antiangiogenic effect in the research against glioblastoma and other cancers.
Integrin   Autophagy   Apoptosis   STAT   PD-1/PD-L1  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Digestive System Inflammation   SARS-CoV-2 Infection   Obesity  
74
HY-N0822 Shikonin
Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent TMEM16A chloride channel inhibitor with an IC50 of 6.5 μM. Shikonin is a specific pyruvate kinase M2 (PKM2) inhibitor and can also inhibit TNF-α and NF-κB pathway. Shikonin decreases exosome secretion through the inhibition of glycolysis. Shikonin inhibits AIM2 inflammasome activation.
Exosomes   Chloride Channel   Pyruvate Kinase   NF-κB   TNF Receptor   HIV   AIM2  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Depression   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
72
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

PD-1/PD-L1   Apoptosis   Autophagy  
Colorectal Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
40
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
35
HY-N0182 Fisetin
Fisetin is a natural flavonol found in many fruits and vegetables with various benefits, such as antioxidant, anticancer, neuroprotection effects.
Sirtuin   PPAR   TNF Receptor  
Digestive System Disease   Prostate Cancer   Viral Infection   Depression   Digestive System Inflammation   SARS-CoV-2 Infection   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
34
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
PD-1/PD-L1   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
32
HY-P9970 Infliximab
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research.
The component ratio of this product is Active ingredient : Excipients = 9 : 47.

Species: Human

TNF Receptor  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease   Lung Cancer   Breast Cancer  
27
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
27
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
PD-1/PD-L1   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
26
HY-N0171A Beta-Sitosterol (purity>98%)
Beta-Sitosterol (purity>98%) is orally active. Beta-Sitosterol exhibits multiple activities, including anti-inflammatory, anticancer, antioxidant, antimicrobial, antidiabetic, antioxidant enzyme, and analgesic. Beta-Sitosterol inhibits inflammation and impaired adipogenesis in bovine mammary epithelial cells by reducing levels of ROS, TNF-α, IL-1β, and NF-κB p65 and restoring the activity of the HIF-1α/mTOR signaling pathway. Beta-Sitosterol induces apoptosis in cancer cells through ROS-mediated mitochondrial dysregulation and p53 activation. Beta-Sitosterol exerts its anticancer effects in cancer cells by activating caspase-3, caspase-8, and caspase-9, mediating PARP inactivation, MMP loss, altered Bcl-2-Bax ratio, and cytochrome c release. Beta-Sitosterol modulates macrophage polarization and reduces rheumatoid inflammation in mice. Beta-Sitosterol inhibits tumor growth in multiple mouse cancer models. Beta-Sitosterol can be used in the research of arthritis, lung cancer, breast cancer and other cancers, diabetes, etc.
Bacterial   Apoptosis   Reactive Oxygen Species (ROS)   MDM-2/p53   Caspase   PARP   MMP   Bcl-2 Family   HIF/HIF Prolyl-Hydroxylase   TNF Receptor   Interleukin Related   NF-κB   mTOR   Lactate Dehydrogenase   CDK   Glutathione Peroxidase   SOD  
Lung Cancer   Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Bacterial Infection   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
23
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
23
HY-P9908 Adalimumab
Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).

Species: Human

TNF Receptor   Bacterial  
Cancer   Autoimmune Disease  
20
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

PD-1/PD-L1  
Colorectal Cancer  
19
HY-108847 Etanercept
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis.
TNF Receptor   Bacterial  
Cancer   Rheumatoid Arthritis  
15
HY-P9913A Rituximab (anti-CD20)
Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer.

Species: Human

CD20  
Triple-Negative Breast Cancer   Acute Myeloid Leukemia   Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma   Multiple Myeloma   Multiple Sclerosis   Sickle Cell Disease   Rheumatoid Arthritis  
14
HY-P9913 Rituximab
Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.

Species: Human

Radionuclide-Drug Conjugates (RDCs)   CD20  
Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma   Systemic Lupus Erythematosus   Myasthenia gravis   Multiple Sclerosis   Rheumatoid Arthritis  
14
HY-U00451 ATP-Red 1
ATP-Red 1 is a multisite-binding switchable fluorescent probe, and can selectively and rapidly responds to intracellular concentrations of ATP in living cells (Ex/Em = 510/590 nm).
Fluorescent Dye  
12
HY-148905 p-Aminophenylmercuric acetate
p-Aminophenylmercuric acetate is an organomercurial activator of matrix metalloproteinases (MMP). P-Aminophenylmercuric acetate participates in the activation and inhibition of MMP-8 by attacking protein sulfhydryl or inducing cysteine switching reaction. p-Aminophenylmercuric acetate promotes the shedding of betacellulin precursor (pro-BTC). p-Aminophenylmercuric acetate influences the binding of agonists and antagonists to the opiate receptor.
Cathepsin   MMP  
Infection  
11
HY-N0284 Esculetin
Esculetin is an active ingredient extracted mainly from the bark of Fraxinus rhynchophylla. Esculetin inhibits platelet-derived growth factor (PDGF)-induced airway smooth muscle cells (ASMCs) phenotype switching through inhibition of PI3K/Akt pathway. Esculetin has antioxidant, antiinflammatory, and antitumor activities.
PI3K   Akt  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
8
HY-107632 GYY4137
GY4137 is a sustained-release H2S donor possessing vasodilatory, antihypertensive, and anti-inflammatory activities. GY4137 can inhibit cell growth, induce apoptosis, and cause cell cycle arrest by blocking the STAT3 pathway, demonstrating potent anticancer activity.
Apoptosis   STAT   NF-κB   NO Synthase   COX   TNF Receptor   Interleukin Related  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
8
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

PD-1/PD-L1  
Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
6
HY-P9952 Belimumab
Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research. The component ratio of this product is Active ingredient: Excipients = 1:1.0-1:1.2.

Species: Human

TNF Receptor   CD20  
Blood Disease   Systemic Lupus Erythematosus   Myasthenia gravis   Rheumatoid Arthritis  
5
HY-P80616 c-Fos Antibody
c-Fos Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to c-Fos.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

4
HY-108831A Natalizumab (Anti-CD49d)
Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4+ T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses.

Species: Human

Integrin  
Digestive System Disease   Melanoma   Digestive System Inflammation   Experimental Autoimmune Encephalomyelitis   Multiple Sclerosis   Crohn's Disease   Experimental Autoimmune Encephalomyelitis   Rheumatoid Arthritis  
3
HY-108831 Natalizumab
Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4+ T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses.

Species: Human

Integrin  
Leukemia/Lymphoma/Myeloma   Experimental Autoimmune Encephalomyelitis   Multiple Sclerosis   Experimental Autoimmune Encephalomyelitis  
3
HY-P9963 Blinatumomab
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia.

Species: Human

CD19  
Cancer  
3
HY-P702574 MLKL Protein, Human (His)
MLKL protein is a pseudokinase that plays a key role in TNF-induced necroptosis. Despite lacking intrinsic kinase activity, it is activated through RIPK3 phosphorylation, leading to homotrimerization, plasma membrane localization, and execution of necroptosis. MLKL Protein, Human (His) is the recombinant human-derived MLKL protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

Enzymes & Regulators Kinases Transferases (EC 2) Serine/Threonine Kinase Proteins Pseudokinases TKL TKL-Unique MLKL

3
HY-P99711 Loncastuximab
Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab has antitumor activity and can be used in the research of Non-Hodgkin Lymphoma (NHL) and Diffuse Large B-cell Lymphoma (DLBCL). Loncastuximab is capable of synthesizing the ADC molecule Loncastuximab tesirine (HY-P99349).

Species: Human

CD19   ADC Antibodies  
Cancer  
2
HY-P9981 Tafasitamab
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19.

Species: Human

Apoptosis  
Cancer   Inflammation or Immune System Disease  
2
HY-P99931 Epcoritamab
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20+ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines.

Species: Human

CD3   CD20  
Chronic Lymphocytic Leukemia   Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
2
HY-P1304A CART(55-102)(human) TFA
CART(55-102)(human) TFA is a human satiety factor with potent appetite-suppressing activity. CART(55-102)(human) TFA is closely associated with leptin and neuropeptide Y.
Neuropeptide Y Receptor  
Neurological, Eye or Ear Disease  
1
HY-133535 PA Janelia Fluor® 646, SE
PA Janelia Fluor 646, SE (PA-JF646-NHS) is a photo-activatable fluorescent dye. PA Janelia Fluor 646, SE is a far-red light-excited, 405 nm-activated NHS ester-based dye. Janelia Fluor fluorescent dyes can be chemically conjugated to the specific HaloTag substrate (a chloroalkane ligand) to form a fluorescent ligand, rather than binding directly to the HaloTag protein itself. PA Janelia Fluor 646, SE can achieve extremely low background and single-molecule-level ultra-high-resolution imaging through photo-controlled switching, making it a powerful tool for live cell super-resolution microscopy technology (Ex/Em = 646/664 nm).
Fluorescent Dye  
1
HY-P2196A ELA-32(human) TFA
ELA-32(human) TFA is a potent, high affinity apelin receptor agonist (IC50=0.27 nM; Kd=0.51 nM). ELA-32(human) TFA exhibits no binding GPR15 and GPR25. ELA-32(human) TFA activates the PI3K/AKT pathway and promotes self-renewal of hESCs via cell-cycle progression and protein translation. ELA-32(human) TFA also potentiates the TGFβ pathway, priming hESCs toward the endoderm lineage. ELA-32(human) TFA stimulates angiogenesis in HUVEC cells.
Apelin Receptor (APJ)  
Cancer  
1
HY-P1304 CART(55-102)(human)
CART(55-102)(human) is an endogenous satiety factor with potent appetite-suppressing activity. CART(55-102)(human) is closely associated with leptin and neuropeptide Y.
Neuropeptide Y Receptor  
Neurological, Eye or Ear Disease  
1
HY-P99236 Bexmarilimab
Bexmarilimab (FP-1305) is a potent humanized anti-CLEVER-1 IgG4 antibody with an IC50 value of 4.51 nM. Bexmarilimab is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab can promote antigen presentation and pro-inflammatory cytokine secretion. Bexmarilimab can induce B-cell and T-cell activation. Bexmarilimab can be used in researches of immunology and cancer, such as colorectal carcinoma.

Species: Human

Transmembrane Glycoprotein  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer  
1
HY-P99285 Denintuzumab
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia.

Species: Human

ADC Antibodies   CD19  
Leukemia/Lymphoma/Myeloma  
1
HY-W041019 5-Hydroxytryptophol
5-Hydroxytryptophol is a mammalian serotonin metabolite that can be used as a sensitive biomarker for recent alcohol intake. 5-Hydroxytryptophol is formed by alcohol-induced changes in the serotonin metabolic pathway and is excreted in the urine as a glucuronic acid conjugate. 5-Hydroxytryptophol is elevated in urine excretion and can be used clinically to monitor alcohol intake in scenarios such as alcohol relapse.
Endogenous Metabolite  
Metabolic or Endocrine Disease  
1
HY-153084A CD19 CAR mRNA (Human)
CD19 CAR mRNA (Human) expresses CAR protein that specifically targets human CD19. CD19 CAR mRNA can trigger transitory expression of CAR, allowing T cells to be targeted without permanent genetic modification. CD19 CAR mRNA targets CD19 which is a transmembrane glycoprotein primarily expressed on B lymphocytes and is important in B cell activation. CD19 CAR mRNA can be studied in cancer research such as lymphoma and leukemia.
mRNA   CD19  
Cancer  
1
HY-P99117 Cadonilimab
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC).

Species: Human

PD-1/PD-L1   CTLA-4  
Inflammation or Immune System Disease   Gastric Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P99264 Inotuzumab
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma.

Species: Human

ADC Antibodies   CD22   Apoptosis  
Acute Lymphoblastic Leukemia   Non-Hodgkin Lymphoma  
1
HY-D1056B3 Lipopolysaccharides, from Klebsiella pneumoniae
Lipopolysaccharides, from Klebsiella pneumoniae (LPS, from bacterial (Klebsiella pneumoniae)) are lipopolysaccharide endotoxins and TLR4 activators derived from Klebsiella pneumoniae, and are classified as S-type LPS. Lipopolysaccharides, from Klebsiella pneumoniae exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from Klebsiella pneumoniae may participate in bacterial immune evasion by inhibiting complement-mediated killing and suppressing the host's secretion of antimicrobial peptides, thereby allowing the bacteria to escape immune defenses. Lipopolysaccharides, from Klebsiella pneumoniae possess high viscosity and resistance to serum-mediated killing, which may lead to sepsis. Lipopolysaccharides, from Klebsiella pneumoniae can be used to construct Acute Lung Injury Model.
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
1
HY-158105 ARV-393
ARV-393 is a BCL6 PROTAC degrader. ARV-393 forms a complex with BCL6 and Cereblon, induces BCL6 ubiquitination, and mediates BCL6 degradation via the ubiquitin-proteasome system. ARV-393 enhances CD20 expression, interferon pathway activity and antigen presentation. ARV-393 induces tumor growth inhibition and regression. ARV-393 can be used in research related to non-Hodgkin's lymphoma, high-grade B-cell lymphoma, diffuse large B-cell lymphoma, Burkitt's lymphoma and follicular lymphoma.
PROTACs   BCL6   CD20   IFNAR  
Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
1
HY-P99113 Inebilizumab
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research.

Species: Human

ADC Antibodies   CD19  
Myasthenia gravis   Multiple Sclerosis  
1
HY-P9910 Obinutuzumab (FUT8-KO)
Obinutuzumab (GA101) a Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.

Species: Human

CD20  
Chronic Lymphocytic Leukemia   Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
1
HY-P99033 Mosunetuzumab
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs).

Species: Human

CD20   CD3  
Cancer Immunology   Non-Hodgkin Lymphoma  
1
HY-P99024 Glofitamab
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL).

Species: Human

CD20   CD3  
Cancer   Inflammation or Immune System Disease  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P990007 Tulisokibart
Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody. Tulisokibart targets to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) and ulcerative colitis.

Species: Human

TNF Receptor  
Digestive System Inflammation   Crohn's Disease   Ulcerative Colitis  
1
HY-15579BG MMAF sodium (GMP)
MMAF sodium GMP is a GMP grade MMAF (sodium) (HY-15579B). MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A.
Microtubule/Tubulin   ADC Payloads  
Cancer  
/
HY-15579G MMAF (GMP)
MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A.
Microtubule/Tubulin   ADC Payloads  
Cancer  
/
HY-P990304A Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1-Mouse IgG2a)
Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1-Mouse IgG2a) is a mouse-derived IgG2a κ antibody inhibitor that targets mouse 4-1BBL/CD137L. Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1-Mouse IgG2a) is a chimeric version of the original TKS-1 antibody (HY-P990304). The variable domain sequences are identical to the original TKS-1 but the constant region sequences have been switched from rat IgG2a to mouse IgG2a. Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1-Mouse IgG2a) reacts with mouse 4-1BB ligand (4-1BBL). Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1-Mouse IgG2a) can be used for the researches of cancer, infection, inflammation and immunology.

Species: Mouse

TNF Receptor  
Cancer   Infection   Inflammation or Immune System Disease  
/
HY-182096C DSPE-PEG5000-MG1
DSPE-PEG5000-MG1 is a PEG compound which composed of DSPE and a MG1 peptide (HY-P11315). MG1 peptide is a M1 Microglia-targeting peptide. MG1 peptide can conjugate to anoparticles, crossing the BBB to precisely M1 microglia recognition and achieving controlled release and specific accumulation of drugs through intelligent molecular switching. DSPE-PEG5000-KTP can be used for drug delivery.
Liposome  
Neurological, Eye or Ear Disease  
/
HY-P992155 Arevirumab
Arevirumab (Arevirumab-3) is a pan-lineage neutralizing human monoclonal antibody cocktail (8.9F, 12.1F, 37.D). Arevirumab protects cynomolgus monkeys from severe Lassa fever caused by lineage II and III LASV isolates. Arevirumab is applicable to research related to Lassa fever.

Species: Lassa virus

Arenavirus  
Viral Infection  
/
HY-P11903 dTBP-3
dTBP-3 is a fully D-configured polypeptide competitive inhibitor that targets TIGIT. dTBP-3 can competitively occupy the binding interface between TIGIT and its ligand PVR, block TIGIT-mediated immunosuppressive signals, and reverse the immune exhaustion of NK cells and CD8+ T cells. dTBP-3 possesses anti-proteolytic activity and tumor tissue penetration ability, and can also enhance the tumor penetration capacity and cellular internalization efficiency of nanocarriers. dTBP-3 can be used in studies related to liver cancer, triple-negative breast cancer and non-small cell lung cancer.
Transmembrane Glycoprotein   Drug Intermediate  
Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
/
HY-P990304B Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1)
Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1) is a mouse-derived IgG1 κ antibody inhibitor that targets mouse 4-1BBL/CD137L. Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1) is a chimeric version of the original TKS-1 antibody (HY-P990304). The variable domain sequences are identical to the original TKS-1 but the constant region sequences have been switched from rat IgG2a to mouse IgG1. Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1) contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1) reacts with mouse 4-1BB ligand (4-1BBL). Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1) can be used for the researches of cancer, infection, inflammation and immunology.

Species: Mouse

TNF Receptor  
Cancer   Infection   Inflammation or Immune System Disease  
/
HY-N15781 Trans-faazo-4
Trans-FAAzo-4 is a photo-switchable fatty acid analogue used in photo-pharmacology. Trans-FAAzo-4 is able to alter membrane lateral pressure and thus control opening and closing of mechanosensitive ion channels.
Biochemical Assay Reagents  
Metabolic or Endocrine Disease  
/
HY-W700452 Y-27632-d4 hydrochloride hydrate
Y-27632-d4 hydrochloride hydrate is the deuterium labeled Y-27632 hydrochloride hydrate (HY-10071A). Y-27632 hydrochloride hydrate is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with Kis of 220 and 300 nM, respectively. Y-27632 hydrochloride hydrate attenuates Doxorubicin-induced apoptosis of human cardiac stem cells. Y-27632 hydrochloride hydrate also suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells. Y-27632 hydrochloride hydrate primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation.
Isotope-Labeled Compounds   ROCK   Apoptosis  
Cancer  
/
HY-182096A DSPE-PEG2000-MG1
DSPE-PEG2000-MG1 is a PEG compound which composed of DSPE and a MG1 peptide (HY-P11315). MG1 peptide is a M1 Microglia-targeting peptide. MG1 peptide can conjugate to anoparticles, crossing the BBB to precisely M1 microglia recognition and achieving controlled release and specific accumulation of drugs through intelligent molecular switching. DSPE-PEG2000-KTP can be used for drug delivery.
Liposome  
Neurological, Eye or Ear Disease  
/
HY-182096B DSPE-PEG3400-MG1
DSPE-PEG3400-MG1 is a PEG compound which composed of DSPE and a MG1 peptide (HY-P11315). MG1 peptide is a M1 Microglia-targeting peptide. MG1 peptide can conjugate to anoparticles, crossing the BBB to precisely M1 microglia recognition and achieving controlled release and specific accumulation of drugs through intelligent molecular switching. DSPE-PEG3400-KTP can be used for drug delivery.
Liposome  
Neurological, Eye or Ear Disease  
/
HY-N15785 18:0-Azo PC
18:0-azo PC is an analog of phosphatidylcholine (PC). Under light, 18:0-azo PC can be switched on and off by light, forcing the azobenzene portion of the molecule to undergo cis/trans isomerization, leading to the initiation or termination of cell signaling.
Biochemical Assay Reagents  
Metabolic or Endocrine Disease  
/
HY-10224S Panobinostat-d4
Panobinostat-d4 is the deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].
HDAC   Autophagy   HIV   Apoptosis  
Cancer  
/
HY-N18979A trans-p-Coumaric acid 4-O-β-D-glucopyranoside
trans-p-Coumaric acid 4-O-β-D-glucopyranoside is an orally active phenolic glycoside and hydroxycinnamic acid derivative with high plasma exposure following oral administration in mice. trans-p-Coumaric acid 4-O-β-D-glucopyranoside can be used in studies related to allergic contact dermatitis.
Amino Acid Derivatives  
Contact Dermatitis  
/
HY-10224S1 Panobinostat-d4 hydrochloride
Panobinostat-d4 (hydrochloride) is deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].
Isotope-Labeled Compounds   HDAC   Autophagy   HIV   Apoptosis  
Cancer  
/
HY-P990270 Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1)
Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to mouse CD40L/CD154. Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) is a chimeric version of the original MR-1 antibody (HY-P990134). The variable domain sequences are identical to the original MR-1 but the constant region sequences have been switched from Armenian hamster IgG to mouse IgG1. Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) blocks CD40/CD40L signaling. Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) can be used for researches of cancer, inflammation and immunology.

Species: Mouse

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-12288S Ozanimod-d6
Ozanimod-d6 (RPC-1063-d6) is the deuterium labeled Ozanimod (HY-12288). Ozanimod (RPC-1063) is a CNS-penetrant sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5). Ozanimod has modulate effect for hS1P1 and hS1P5 receptor with EC50s of 1.03 nM and 8.6 nM, respectively. Ozanimod can be used for the research of relapsing multiple sclerosis (MS).
Isotope-Labeled Compounds   LPL Receptor  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-P1305A CART(55-102)(rat) TFA
CART(55-102)(rat) TFA is a rat satiety factor with potent appetite-suppressing activity. CART(55-102)(rat) TFA is closely associated with leptin and neuropeptide Y. CART(55-102)(rat) TFA can induces anxiety and stress-related behavior.
Neuropeptide Y Receptor  
Neurological, Eye or Ear Disease  
/
HY-10446S1 Pralatrexate-13C5,15N
Pralatrexate-13C5,15N is the 13C- and 15N-labeled Pralatrexate (HY-10446). Pralatrexate is an antifolate and is a potent dihydrofolate reductasean (DHFR) inhibitor with a Ki of 13.4 pM. Pralatrexate is a substrate for folylpolyglutamate synthetase with improved cellular uptake and retention. Pralatrexate has antitumor activities and has the potential for relapsed/refractory T-cell lymphoma treatment. Pralatrexate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Isotope-Labeled Compounds   Apoptosis   Antifolate  
Cancer  
/
HY-D3269 Mito-Cu(II)
Mito-Cu (II) is a mitochondria-targeted fluorescent probe (Ex/Em = 370/450 nM). Mito-Cu (II) specifically accumulates in mitochondria of living cells and enables real-time detection of exogenous Cu2+ within mitochondria of living cells. Mito-Cu (II) achieves "on-off-on" fluorescence switching through sequential exposure to Cu2+ and ethylenediaminetetraacetic acid (EDTA) (HY-Y0682). Its fluorescence is quenched after forming a 1:1 complex with Cu2+, and the fluorescence recovers when Cu2+ is chelated by EDTA.
Fluorescent Dye  
/
HY-P4975 CART (61-102) (rat)
CART (61-102) (rat) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development.
Others  
/
HY-P11892 c10c-G1V3
c10c-G1V3 is a BRAG2 binder with a Kd value of 7.37 μM. c10c-G1V3 binds to BRAG2, thereby disrupting its interaction with GluA2 and blocking GluA2 endocytosis and AMPAR subunit switching. c10c-G1V3 reduces glutamate-induced intracellular reactive oxygen species (ROS) accumulation and cell apoptosis (apoptosis). c10c-G1V3 decreases infarct volume in the transient middle cerebral artery occlusion model. c10c-G1V3 can be used in studies related to ischemic stroke.
iGluR   Apoptosis   Reactive Oxygen Species (ROS)   Bcl-2 Family  
Ischemic Stroke  
/
HY-P11129 MAGE-A4 (286-294)
MAGE-A4 (286-294) is a polypeptide derived from the 286th to 294th amino acids of the MAGE-A4 protein. MAGE-A4 (286-294) binds HLA-­A*02 with an affinity of 560.08 nM and an IC50 of 8.52 nM. MAGE-A4 (286-294) can be detected in various types of cancers (such as esophageal cancer, lung squamous cell carcinoma, bladder cancer). MAGE-A4 (286-294) can be used to produce CAR-T cells and to develop CAR-T cell therapy.
Others  
Cancer  
/
HY-P3692 CART (55-76), rat
CART (55-76), rat is a neuropeptide (55-76 residues of the CART peptide) and constitutes the N-terminal fragments of CART (55-102). CART (55-76), rat is a rat satiety factor with potent appetite-suppressing activity and is closely associated with leptin and neuropeptide Y. CART (55-76), rat can induce anxiety and stress-related behavior.
Neuropeptide Y Receptor  
Neurological, Eye or Ear Disease  
/
HY-P1303A CART(62-76)(human,rat) TFA
CART(62-76)(human,rat) TFA is a neuropeptide (62-76 residues of the CART peptide) with neurotransmitter-like effects. CART(62-76)(human,rat) TFA can modulate the activity of striatal noradrenergic and corticostriatal and hypothalamic serotoninergic (5-HT) system in the rat brain.
5-HT Receptor  
Neurological, Eye or Ear Disease  
/
HY-182096 DSPE-PEG1000-MG1
DSPE-PEG1000-MG1 is a PEG compound which composed of DSPE and a MG1 peptide (HY-P11315). MG1 peptide is a M1 Microglia-targeting peptide. MG1 peptide can conjugate to anoparticles, crossing the BBB to precisely M1 microglia recognition and achieving controlled release and specific accumulation of drugs through intelligent molecular switching. DSPE-PEG1000-KTP can be used for drug delivery.
Liposome  
Neurological, Eye or Ear Disease  
/
HY-P2632 RAD16-I
RAD16-I (RADA16) is a non-directed self-assembling peptide hydrogel. Under physiological conditions, RAD16-I spontaneously forms a three-dimensional nanofiber network that mimics the extracellular matrix, and possesses excellent properties such as high water content, biocompatibility and degradability. RAD16-I serves as an ideal scaffold for three-dimensional cell culture. RAD16-I not only maintains cell viability and induces self-organization, but also supports cell adhesion, proliferation, differentiation and insulin secretion, effectively stabilizes islet clusters and promotes directed differentiation of the cardiac lineage. RAD16-I can construct a cell-friendly nano-microenvironment for research related to diseases such as myocardial infarction and diabetes.
Biochemical Assay Reagents  
Neurological, Eye or Ear Disease  
/
HY-P11925 CPP44
CPP44 is a tumor lineage-homing cell-penetrating peptide (CPP) that selectively enters myeloid leukemia cells and liver tumor cells. The cellular internalization of CPP44 is associated with M160 (CD163L1), and it mainly enters cells via an ATP- and dynein-dependent, clathrin-independent endocytic pathway. CPP44 can be used in studies related to acute myeloid leukemia, hepatocellular carcinoma, tumor-targeted delivery, and tumor imaging.
Small Interfering RNA (siRNA)  
Liver Cancer   Acute Myeloid Leukemia  
/
HY-N7122R Thymopentin (Standard)
Thymopentin is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs).
Reference Standards   Endogenous Metabolite  
Cancer   Inflammation or Immune System Disease  
/
HY-N15775 Ace-1
ACe-1 is a ceramide derivative with an azobenzene moiety to allow for optical control of the N-acyl chain. ACe-1 is capable of reversibly switching lipid domains in a raft-like bilayer membrane.

Source: plasma membrane of eukaryotic cells

Biochemical Assay Reagents  
/
HY-P991839 Anti-CD19 Antibody (FMC63)
Anti-CD19 Antibody (FMC63) is an antibody that binds to CD19, with a human Kd value ranging from 0.42 nM to 149 nM. Anti-CD19 Antibody (FMC63) mediates tumor cell killing, cytokine secretion, stable CAR expression, T cell activation and memory differentiation. Anti-CD19 Antibody (FMC63) fails to eliminate lymphoma cells carrying CD19 point mutations or co-expressing FMC63-CAR19, induces higher levels of activation-induced cell death, and reduces cell persistence. Anti-CD19 Antibody (FMC63) can be used in research related to B-cell non-Hodgkin's lymphoma, B-cell acute lymphoblastic leukemia, relapsed or refractory diffuse large B-cell lymphoma, etc.

Species: Human

CD19  
Acute Lymphoblastic Leukemia   Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
/
HY-141432G NX-1607 (GMP)
NX-1607 (Cbl-b-IN-3) (GMP) is a GMP-grade NX-1607 (HY-141432). GMP-grade small molecules can be used as adjuvant agents in cell therapy. NX-1607 (GMP) enhances antigen recall, reduces T cell exhaustion and increases cytokine production. NX-1607 is an inhibitor of Cbl-b (an E3 enzyme).
E1/E2/E3 Enzyme  
Cancer   Inflammation or Immune System Disease  
/
HY-P990304C Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1)
Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1) is a mouse-derived IgG2a κ antibody inhibitor that targets mouse 4-1BBL/CD137L.Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1) is a chimeric version of the original TKS-1 antibody (HY-P990304). The variable domain sequences are identical to the original TKS-1 but the constant region sequences have been switched from rat IgG2a to mouse IgG2a. Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1) reacts with mouse 4-1BB ligand (4-1BBL). Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1) can be used for the researches of cancer, infection, inflammation and immunology.

Species: Mouse

TNF Receptor  
Cancer   Infection   Inflammation or Immune System Disease  
/
HY-W041019R 5-Hydroxytryptophol (Standard)
5-Hydroxytryptophol is a mammalian serotonin metabolite that can be used as a sensitive biomarker for recent alcohol intake. 5-Hydroxytryptophol is formed by alcohol-induced changes in the serotonin metabolic pathway and is excreted in the urine as a glucuronic acid conjugate. 5-Hydroxytryptophol is elevated in urine excretion and can be used clinically to monitor alcohol intake in scenarios such as alcohol relapse.
Reference Standards   Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-N7122AR Thymopentin acetate (Standard)
Thymopentin (acetate) (Standard) is the analytical standard of Thymopentin (acetate) (HY-N7122A). This product is intended for research and analytical applications. Thymopentin acetate is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin acetate is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin acetate enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs).
Reference Standards   Endogenous Metabolite  
/
HY-P990930 Mozistobart
HY-P990930 is an CD22-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

CD22   Antibody-Oligonucleotide Conjugates (AOCs)  
Inflammation or Immune System Disease  
/
HY-153939S Idasanutlin-d3-1
Idasanutlin-d3-1 (RG7388-d3-1) is the deuterated-labeled Idasanutlin (HY-15676). Idasanutlin (RG7388) is an orally bioavailable MDM2 inhibitor with an IC50 of 6 nM. Idasanutlin disrupts MDM2-p53 binding, stabilizes and activates p53, triggering cell cycle arrest, apoptosis, and reduced cancer cell viability. Idasanutlin reduces EGFR protein expression and phosphorylation, suppresses downstream SHP2, MEK1/2, ERK1/2, AKT, mTOR, p70(S6K1), and S6 signaling. Idasanutlin induces mitochondrial ROS production, drives p38 MAPK phosphorylation, upregulates NOXA, and mediates caspase-3-dependent apoptosis and gasdermin E-mediated pyroptosis. Idasanutlin can be used for the research of TP53-mutant non-small cell lung cancer, T-cell acute lymphoblastic leukemia, colorectal carcinoma, melanoma, diffuse large B-cell lymphoma, mantle cell lymphoma, non-Hodgkin lymphoma, severe fever with thrombocytopenia syndrome, neuroblastoma, acute lymphoblastic leukemia, relapsed or refractory acute myeloid leukemia, osteosarcoma, solid tumors, and hematological tumors.
Isotope-Labeled Compounds   MDM-2/p53   E1/E2/E3 Enzyme   Apoptosis   Pyroptosis   Reactive Oxygen Species (ROS)   Caspase  
Musculoskeletal and Skin Disease   Colorectal Cancer   Melanoma   Neuroblastoma   Osteosarcoma   Non-Small Cell Lung Cancer   Acute Myeloid Leukemia   Non-Hodgkin Lymphoma  
/
HY-N0811 Anemarsaponin B
Anemarsaponin B is a steroidal saponin. Anemarsaponin B decreases the protein and mRNA levels of iNOS and COX-2. Anemarsaponin B reduces the expressions and productions of pro-inflammatory cytokines, including TNF-a and IL-6. Anemarsaponin B inhibits the nuclear translocation of the p65 subunit of NF-κB by blocking the phosphorylation of IκBα. Anemarsaponin B also inhibits the phosphorylation of MAP kinase kinases 3/6 (MKK3/6) and mixed lineage kinase 3 (MLK3). Anti-inflammatory effect .
NO Synthase   COX   NF-κB   MEK  
Inflammation or Immune System Disease  
/
HY-P3691 CART (1-39), Human
CART (1-39), Human, Rat is a neuropeptide consisting of 1-39 residues of the CART peptide. CART (1-39), Human, Rat is a rat satiety factor with potent appetite-suppressing activity and is closely associated with leptin and neuropeptide Y. CART (1-39), Human, Rat inhibits both normal and starvation-induced feeding. CART (1-39), Human, Rat can induce anxiety and stress-related behavior.
Neuropeptide Y Receptor  
Neurological, Eye or Ear Disease  
/
HY-P11108A RP-182 acetate
RP-182 acetate is a synthetic immunomodulatory peptide that exerts anti-tumor effects by targeting the mannose receptor CD206 (Kd = 8 μM) on the surface of tumor-associated macrophages (TAMs). RP-182 acetate induces a conformational switch of the CD206 receptor, which activates NF-κB signaling and phagocytosis in CD206high TAMs. RP-182 acetate has dual function: activation of canonical NF-κB signaling, triggering TNFα secretion and autocrine activation of the TNF receptor 1 (TNFR1), leading to activation of caspase 8, apoptosis, and cell death. RP-182 acetate is used in pancreatic cancer and melanoma research.
NF-κB   Apoptosis   TNF Receptor   Caspase  
Cancer   Inflammation or Immune System Disease  
/
HY-P990269 Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1)
Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse CD40L/CD154. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) is a chimeric version of the original MR-1 antibody (HY-P990134). The variable domain sequences are identical to the original MR-1 but the constant region sequences have been switched from Armenian hamster IgG to mouse IgG2a. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) blocks CD40/CD40L signaling. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) can be used for researches of cancer, inflammation and immunology.

Species: Mouse

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-13010S Laquinimod-d5
Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research.
Isotope-Labeled Compounds   NF-κB   Apoptosis  
Inflammation or Immune System Disease  
/
HY-P990172 Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG1. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) can be used for the research of cancer.

Species: Mouse

PD-1/PD-L1  
Cancer  
/
HY-P1303 CART(62-76)(human,rat)
CART(62-76)(human,rat) is a neuropeptide (62-76 residues of the CART peptide) with neurotransmitter-like effects. CART(62-76)(human,rat) can modulate the activity of striatal noradrenergic and corticostriatal and hypothalamic serotoninergic (5-HT) system in the rat brain.
5-HT Receptor  
Neurological, Eye or Ear Disease  
/
HY-16046S Rimiducid-d4
Rimiducid-d4 (AP1903-d4) is the deuterium labeled Rimiducid (HY-16046). Rimiducid (AP1903) is a dimerizer agent that acts by cross-linking the FKBP domains. Rimiducid (AP1903) dimerizes the Caspase 9 suicide switch and rapidly induces apoptosis.
Isotope-Labeled Compounds   Apoptosis   FKBP  
Cancer  
/
HY-N0284R Esculetin (Standard)
Esculetin (Standard) is the analytical standard of Esculetin. This product is intended for research and analytical applications. Esculetin is an active ingredient extracted mainly from the bark of Fraxinus rhynchophylla. Esculetin inhibits platelet-derived growth factor (PDGF)-induced airway smooth muscle cells (ASMCs) phenotype switching through inhibition of PI3K/Akt pathway. Esculetin has antioxidant, antiinflammatory, and antitumor activities.
Reference Standards   PI3K   Akt  
Cancer   Inflammation or Immune System Disease  
/
HY-P99027 Ieramilimab
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors.

Species: Human

LAG-3  
Triple-Negative Breast Cancer  
/
HY-P11108 RP-182
RP-182 is a synthetic immunomodulatory peptide that exerts anti-tumor effects by targeting the mannose receptor CD206 (Kd = 8 μM) on the surface of tumor-associated macrophages (TAMs). RP-182 induces a conformational switch of the CD206 receptor, which activates NF-κB signaling and phagocytosis in CD206high TAMs. RP-182 has dual function: activation of canonical NF-κB signaling, triggering TNFα secretion and autocrine activation of the TNF receptor 1 (TNFR1), leading to activation of caspase 8, apoptosis, and cell death. RP-182 is used in pancreatic cancer and melanoma research.
NF-κB   Apoptosis   TNF Receptor   Caspase  
Inflammation or Immune System Disease  
/
HY-P990120 Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5)
Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) is an anti-rat Kappa Immunoglobulin Light Chain IgG2a monoclonal antibody. Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) can enhance B cell depletion. Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) can enhance T cell exhaustion after the injection of CD4 mAb (HY-P990792) and CD8 mAb (HY-P99129). Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) can be used for research on immunology.

Species: Rat

Others  
Inflammation or Immune System Disease  
/
HY-P990283 Anti-Mouse CD22 Antibody (Cy34.1)
Anti-Mouse CD22 Antibody (Cy34.1) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to mouse CD22. Anti-Mouse CD22 Antibody (Cy34.1) can deplete CD22 cells and B cells. Anti-Mouse CD22 Antibody (Cy34.1) can promote microglial phagocytosis. Anti-Mouse CD22 Antibody (Cy34.1) can be used for the researches of inflammation and neurological disease, such as Alzheimer's disease (AD) and neuromyelitis.

Species: Mouse

CD22  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-P991490 ISB2001
ISB2001 is a trispecific antibody targeting CD38, CD3 and BCMA. ISB2001 effectively counteracts tumor immune escape mechanisms caused by antigen downregulation, antigen loss, soluble factor competition and other factors. ISB2001 is applicable to relevant research on multiple myeloma and relapsed/refractory multiple myeloma.

Species: Human

CD38   CD3   TNF Receptor  
Cancer  
/
HY-N7122A Thymopentin acetate
Thymopentin acetate is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin acetate is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin acetate enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs).
Endogenous Metabolite  
Cancer   Inflammation or Immune System Disease   Viral Infection  
/
HY-P9959 Inotuzumab ozogamicin
Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody Inotuzumab (HY-P99264) conjugated to Calicheamicin (HY-19609). Inotuzumab ozogamicin and G544 bind human CD22 with similar affinities (Kd ≈ 150 pM). Inotuzumab ozogamicin has demonstrated efficacy against CD22+ B-cell non-Hodgkin’s lymphoma. Inotuzumab ozogamicin can be used in the research of acute lymphoblastic leukemia.

Species: Human

Antibody-Drug Conjugates (ADCs)   CD22  
Acute Lymphoblastic Leukemia   Non-Hodgkin Lymphoma  
/
HY-N0600 Ginsenoside F3
Ginsenoside F3 is a saponin extracted from the leaves of Panax ginseng with immunoenhancing and antitumor immunostimulatory activities. Ginsenoside F3 upregulates RIPOR2 with a Kd value of 3.77 μM. Ginsenoside F3 enhances NF‑κB activation, upregulates T‑bet and downregulates GATA‑3, increases the production of IL‑2 and IFN‑γ, decreases the production of IL‑4 and IL‑10, reverses CD8⁺ T‑cell exhaustion, restores cytokine secretion, and enhances antitumor immunity in a mouse non‑small cell lung cancer model. Ginsenoside F3 can be used for the research of non-small cell lung cancer.
Interleukin Related   IFNAR   NF-κB  
Digestive System Disease   Cancer Immunology   Digestive System Inflammation  
/
HY-141602 Pinatuzumab vedotin
Pinatuzumab vedotin, an antibody-drug conjugate (ADC), is a CD22 humanized monoclonal antibody Pinatuzumab (HY-P99230) conjugated to VcMMAE (HY-15575). Pinatuzumab vedotin has antitumor activities.
Antibody-Drug Conjugates (ADCs)   CD22   Microtubule/Tubulin  
Cancer  
/
HY-P99613 Favezelimab
Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand, MHC class II molecules. Favezelimab is applicable to research on relapsed/refractory classical Hodgkin lymphoma, relapsed/refractory diffuse large B-cell lymphoma, and relapsed/refractory indolent B-cell lymphoma. For the isotype control of Favezelimab, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Species: Human

LAG-3  
Leukemia/Lymphoma/Myeloma  
/
HY-P991449 LY3415244
LY3415244 is a bispecific antibody that targets and inhibits TIM-3 and PD-L1. LY3415244 blocks the interaction between TIM-3 on immune cells and PD-L1 on the surface of tumor cells, establishes intercellular connections between TIM-3-positive immune cells and PD-L1-positive tumor cells, and blocks dual immunosuppressive signals. LY3415244 alleviates T cell exhaustion and restores T cell proliferation. LY3415244 induces broad-spectrum anti-drug antibodies, which impairs the binding capacity to soluble TIM-3 targets. LY3415244 can be used in research related to various advanced solid tumors.

Species: Human

PD-1/PD-L1   Tim3  
Cancer  
/
HY-P99230 Pinatuzumab
Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Integrin   CD22  
Cancer  
/
HY-W923198 Fluorescein O-methacrylate
Fluorescein O-methacrylate (Methacryloyloxy fluorescein) is a pH-responsive fluorescent monomeric dye. Fluorescein O-methacrylate exhibits pH-responsive fluorescence properties: its fluorescence is activated under alkaline conditions and quenched under neutral or acidic conditions; reversible switching of fluorescence is achievable by adjusting the pH of the solution. Fluorescein O-methacrylate can be used as a monomer for the synthesis of amphiphilic fluorescein polymers. These polymers can self-assemble into stable polymer nanoparticles with enhanced aqueous-phase fluorescence, and also enable the conjugation of nanoparticles with amine-containing biomolecules to support sensitive optical detection of biomarkers (Ex/Em = 490/520 nm).
Fluorescent Dye  
/
HY-P990759 Rezetamig
Rezetamig is a human bispecific antibody that recognizes the CD3 antigen on T-lymphocytes and the CD22 antigen on mature and malignant B-lymphocytes.

Species: Human

CD22   CD3  
Inflammation or Immune System Disease  
/
HY-P1305 CART(55-102)(rat)
CART(55-102)(rat) is a rat satiety factor with potent appetite-suppressing activity. CART(55-102)(rat) is closely associated with leptin and neuropeptide Y. CART(55-102)(rat) can induces anxiety and stress-related behavior.
Neuropeptide Y Receptor  
Neurological, Eye or Ear Disease  
/
HY-P990781 Suciraslimab
Suciraslimab (SM03) is an anti-human CD22 monoclonal antibody. Suciraslimab inhibits NLRP3 and ASC signaling. Suciraslimab suppresses cytokine (IL-1β, IL-12, IL-23) secretion and α4 integrin expression. Suciraslimab improves working memory and neuroinflammation. Suciraslimab isotype control product: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

CD22   NOD-like Receptor (NLR)   Interleukin Related   Integrin  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-P990171 Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG2a. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) can be used for the research of cancer.

Species: Mouse

PD-1/PD-L1  
Cancer  
/
HY-P990980 Cizutamig
Cizutamig (CND-106) is a bispecific T-cell engager targeting BCMA and CD3. Cizutamig exhibits immunostimulatory and anti-tumor activities. Cizutamig can be used in research related to relapsed or refractory multiple myeloma and systemic lupus erythematosus.

Species: Human

CD3  
Cancer   Inflammation or Immune System Disease  
/
HY-I0259 8-Amino-2-naphthol
8-Amino-2-naphthol is a photoactive charge transfer compounds, which can be used as fluorescent probe. 8-Amino-2-naphthol undergoes excited-state proton transfer (ESPT) to form a zwitterion under acidic conditions, where the photoacidity of its hydroxyl group is regulated by the protonation state of the amino group, enabling pH to act as an on/off switch for photoacidity. 8-Amino-2-naphthol is also utilized as chiral organocatalyst.
Fluorescent Dye  
/
HY-P99034 Moxetumomab
Moxetumomab is a CD22-targeting monoclonal antibody that forms the component of Moxetumomab Pasudotox, a recombinant CD22-targeting immunotoxin. Moxetumomab binds to CD22 on malignant B cells and delivers the PE38 toxin domain to tumor cells. Moxetumomab can be used in research on relapsed or refractory hairy cell leukemia.

Species: Human

CD22  
Leukemia/Lymphoma/Myeloma  
/
HY-P991537 Risvutatug
HS-20093 Antibody (GSK5764227 Antibody) is an antibody targeting B7-H3, which can be used to synthesize the ADC HS-20093. HS-20093 Antibody exhibits anti-tumor activity. HS-20093 Antibody can be studied in research for small cell lung cancer, relapsed or refractory osteosarcoma, and advanced solid tumors.

Species: Human

ADC Antibodies   CD276/B7-H3  
Cancer  
/
HY-DY1014 ATP-Red 1 (solution)
ATP-Red 1 (solution) is a multisite-binding switchable fluorescent probe, and can selectively and rapidly responds to intracellular concentrations of ATP in living cells (Ex/Em = 510/590 nm).
Solvent and concentration: DMSO: 1 mM
Fluorescent Dye  
/
HY-P99910 Eluvixtamab
Eluvixtamab (AMG-330) is a bispecific T-cell engager. Eluvixtamab binds to CD33 and CD3 on T cells, thereby promoting T cell-mediated cytotoxicity against CD33+ cells. Eluvixtamab can be used in the research of tumors such as relapsed/refractory acute myeloid leukemia.

Species: Human

CD3   Transmembrane Glycoprotein  
Leukemia/Lymphoma/Myeloma  
/
HY-P99976 Anti-Mouse CD19 Antibody (1D3)
Anti-Mouse CD19 Antibody (1D3) is an IgG2a antibody inhibitor targeting mouse CD19. Anti-Mouse CD19 Antibody (1D3) reduces CD19 expression levels on the surface of B cells. Anti-Mouse CD19 Antibody (1D3) inhibits the replication of peritoneal B-1a cells.

Species: Mouse

CD19  
Inflammation or Immune System Disease  
/
HY-P99313 Quilizumab
Quilizumab (Anti-Human IGHE Recombinant Antibody) is a humanized IgG1κ monoclonal antibody targeting immunoglobulin epsilon (also konwn as: IGHE, IgE). Quilizumab targets the M1-prime fragment of membrane-expressed IGHE/IgE, leading to IGHE/IgE switching and memory B cell depletion. Quilizumab has potential in asthma research.

Species: Human

Apoptosis  
Inflammation or Immune System Disease  
/
HY-P99139 Anti-Mouse IL-1b Antibody (B122)
Anti-Mouse IL-1b Antibody (B122) is an anti-mouse IL-1b IgG monoclonal antibody. Anti-Mouse IL-1b Antibody (B122) enhances ferroptosis and increases levels of reactive oxygen species (ROS) combined with Sulfasalazine (SAS) (HY-14655). Anti-Mouse IL-1b Antibody (B122) can reduce monocyte infiltration and alleviate T cell exhaustion by blocking IL-1β signaling. Anti-Mouse IL-1b Antibody (B122) can be used for researches on cancer and cardiovascular conditions such as oral squamous cell carcinoma (OSCC), glioblastoma (GBM) and heart failure.

Species: Mouse

Interleukin Related   Reactive Oxygen Species (ROS)   Ferroptosis  
Blood or Cardio-cerebrovascular Disease   Glioma  
/
HY-N7122 Thymopentin
Thymopentin is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs).
Endogenous Metabolite  
Cancer   Inflammation or Immune System Disease   Viral Infection  
/
HY-P99113A Inebilizumab (FUT8-KO)
Inebilizumab (FUT8-KO) is an anti-CD19 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.Inebilizumab (FUT8-KO) exhibits enhanced ADCC against B cells and can be used for research on multiple sclerosis and neuromyelitis optica.

Species: Human

CD19  
Multiple Sclerosis  
/
HY-172736 Toviblideg
Toviblideg (BMS-986458) is a highly selective, orally active cereblon-based BCL6 PROTAC degrader and antitumor agent. Toviblideg selectively degrades BCL6 by binding cereblon to the BTB domain of BCL6, thereby regulating the cell cycle, antiproliferative and interferon signaling pathways, and upregulating the expression and distribution of CD20. Toviblideg modulates the phenotype of follicular helper T cells and reduces circulating tumor DNA levels. The combination of Toviblideg with CD20xCD3 bispecific antibody also enhances the efficiency of T cell tumor infiltration and expansion. Toviblideg induces regression of BCL6-positive tumors and prolongs survival, and it is suitable for research related to B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, and relapsed/refractory lymphoma.
PROTACs   BCL6   CD20  
Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
/
HY-P99289 Epratuzumab
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases.

Species: Human

CD22  
Leukemia/Lymphoma/Myeloma   Autoimmune Disease  
/
HY-P9989 Linvoseltamab
Linvoseltamab (REGN5458) is a bispecific T-cell engager (BiTE) antibody that specifically binds to B cell maturation antigen (BCMA) and CD3 of T cells, thereby directing T cells to multiple myeloma (MM) cells expressing BCMA and activating T cells to kill tumor cells. Linvoseltamab can be used in research of relapsed/refractory multiple myeloma (RRMM).

Species: Human

CD3   TNF Receptor  
Cancer  
/
HY-P99868 Duvortuxizumab
Duvortuxizumab (MGD 011) is a chimeric humanized IG antibody targeting CD19 and CD3E.

Species: Human

CD19   CD3  
Cancer  
/
HY-P99761 Obexelimab
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus.

Species: Human

CD19   Apoptosis  
Inflammation or Immune System Disease  
/
HY-P9961 Ofatumumab
Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in CD20-expressing B lymphocytes. Ofatumumab has strong lytic activity against CD20-positive B lymphocytes and eliminates CD20-positive tumor cells through ADCC and CDC. Ofatumumab is particularly effective against drug-resistant cells with low CD20 expression and can be applied to the research of chronic lymphocytic leukemia (CLL).

Species: Human

CD20  
Cancer  
/
HY-P99349 Loncastuximab tesirine
Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). The antibody portion is Loncastuximab (HY-P99711), and the drug-linker conjugate for ADC is Tesirine (HY-128952). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma.
Antibody-Drug Conjugates (ADCs)   Apoptosis  
Cancer  
/
HY-P991028 Surovatamig
Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNγ, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma.

Species: Human

CD3   CD19   Interleukin Related   TNF Receptor   IFNAR  
Non-Hodgkin Lymphoma  
/
HY-P99909 Elranatamab
Elranatamab (PF-06863135) is an anti-CD3E/TNFRSF17 human IgG2κ monoclonal antibody. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).

Species: Human

TNF Receptor  
Inflammation or Immune System Disease  
/
HY-P78917 CD19 Protein, Human (Biotinylated, HEK293, Fc-Avi)
The CD19 protein is a B cell antigen receptor coreceptor that enhances downstream signaling pathways, lowers the activation threshold, and helps B cells respond to antigens. It activates phosphatidylinositol 3-kinase and mobilizes intracellular Ca(2+). CD19 Protein, Human (Biotinylated, HEK293, Fc) is the recombinant human-derived CD19 protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag.

Species: Human; Source: HEK293

CAR-T Related Proteins CD Antigens CD19 B Cell CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins

/
HY-P70505 CD19 Protein, Human (HEK293, Fc)
The CD19 protein is a B cell antigen receptor coreceptor that enhances downstream signaling pathways, lowers the activation threshold, and helps B cells respond to antigens. It activates phosphatidylinositol 3-kinase and mobilizes intracellular Ca(2+). CD19 Protein, Human (HEK293, Fc) is the recombinant human-derived CD19 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Human; Source: HEK293

CAR-T Related Proteins CD Antigens CD19 B Cell CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins

/
HY-P75439 CD19 Protein, Cynomolgus/Rhesus Macaque (HEK293, His)
CD19 is a signaling component of the B-cell receptor complex that lowers the threshold for antigen-driven activation. CD19 Protein, Cynomolgus/Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque, cynomolgus-derived CD19 protein, expressed by HEK293 , with C-His labeled tag.

Species: Rhesus Macaque; Cynomolgus; Source: HEK293

CAR-T Related Proteins CD Antigens CD19 B Cell CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins

/
HY-P76857 CD19 Protein, Cynomolgus/Rhesus Macaque (Biotinylated, HEK293, His)
CD19 is a signaling component of the B-cell receptor complex that lowers the threshold for antigen-driven activation. CD19 Protein, Cynomolgus/Rhesus Macaque (Biotinylated, HEK293, His) is the recombinant Rhesus Macaque-derived CD19 protein, expressed by HEK293 , with C-His labeled tag.

Species: Rhesus Macaque; Cynomolgus; Source: HEK293

CAR-T Related Proteins CD Antigens Biotinylated Proteins CD19 B Cell CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins

/
HY-P74351 CART Protein, Human (HEK293)
CART Protein, a satiety factor, intricately regulates feeding in connection with leptin and neuropeptide Y. It effectively suppresses regular and starvation-triggered feeding, robustly inhibiting neuropeptide Y-initiated feeding within the hypothalamus. Additionally, CART protein plays a pivotal role in fostering neuronal development and survival in vitro, extending beyond its appetite regulation function. CART Protein, Human (HEK293) is the recombinant human-derived CART protein, expressed by HEK293 , with tag free.

Species: Human; Source: HEK293

/
HY-P704306 FITC-Labeled CD19 Protein, Human (HEK293, hFc)
The CD19 protein is a B cell antigen receptor coreceptor that enhances downstream signaling pathways, lowers the activation threshold, and helps B cells respond to antigens. It activates phosphatidylinositol 3-kinase and mobilizes intracellular Ca(2+). FITC-Labeled CD19 Protein, Human (HEK293, hFc) is the recombinant human-derived FITC-Labeled CD19 protein, expressed by HEK293, with C-hFc labeled tag.

Species: Human; Source: HEK293

CAR-T Related Proteins CD Antigens CD19 B Cell CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins

/
HY-P705851 MLKL Protein, Human (sf9, His-GST)
MLKL protein is a pseudokinase that plays a key role in TNF-induced necroptosis. Despite lacking intrinsic kinase activity, it is activated through RIPK3 phosphorylation, leading to homotrimerization, plasma membrane localization, and execution of necroptosis. MLKL, Human (sf9, His-GST) is the recombinant human-derived MLKL protein, expressed by sf9 insect cells, with N-Avi labeled tag.

Species: Human; Source: sf9 insect cells

Kinases Pseudokinases TKL TKL-Unique MLKL

/
HY-P74350 CART Protein, Human (HEK293, Fc)
CART Protein, a satiety factor, intricately regulates feeding in connection with leptin and neuropeptide Y. It effectively suppresses regular and starvation-triggered feeding, robustly inhibiting neuropeptide Y-initiated feeding within the hypothalamus. Additionally, CART protein plays a pivotal role in fostering neuronal development and survival in vitro, extending beyond its appetite regulation function. CART Protein, Human (HEK293, Fc) is the recombinant human-derived CART protein, expressed by HEK293 , with C-mFc labeled tag.

Species: Human; Source: HEK293

/
HY-P74186 E/Envelope Protein, West Nile Virus Lineage 2 (120a.a, P.pastoris, His)
E/Envelope Protein, West Nile Virus Lineage 2 (120a.a, P.pastoris, His) is the recombinant Virus-derived E/Envelope protein, expressed by P. pastoris, with C-His labeled tag.

Species: Virus; Source: P. pastoris

Viral Proteins

/
HY-P74187 E/Envelope Protein, West Nile Virus Lineage 2 (109a.a, P.pastoris, His)
E/Envelope Protein, West Nile Virus Lineage 2 (109a.a, P.pastoris, His) is the recombinant Virus-derived E/Envelope protein, expressed by P. pastoris, with C-His labeled tag.

Species: Virus; Source: P. pastoris

Viral Proteins

/
HY-P74188 E/Envelope Protein, West Nile virus Lineage 1 (120a.a, P.pastoris, His)
E/Envelope Protein, West Nile virus Lineage 1 (120a.a, P.pastoris, His) is the recombinant Virus-derived E/Envelope protein, expressed by P. pastoris, with C-His labeled tag.

Species: Virus; Source: P. pastoris

Viral Proteins

/
HY-P74189 E/Envelope Protein, West Nile Virus Lineage 1 (109a.a, P.pastoris, His)
E/Envelope Protein, West Nile Virus Lineage 1 (109a.a, P.pastoris, His) is the recombinant Virus-derived E/Envelope protein, expressed by P. pastoris, with C-His labeled tag.

Species: Virus; Source: P. pastoris

Viral Proteins

/
HY-P74464 West Nile Virus NS1 Protein (HEK293, His)
West Nile Virus NS1 Protein is a glycoprotein among the flavivirus genus. It is found in both membrane-associated and soluble secreted forms. WNV NS1 has an unusual structure-function because it is glycosylated and forms different structures to facilitate different roles intracellularly and extracellularly, including roles in the replication complex, assisting in virus assembly, and complement antagonism. It also plays a role in protective immunity through antibody-mediated cellular cytotoxicity, and anti-NS1 antibodies elicit passive protection in animal models against a virus challenge. West Nile Virus NS1 Protein (HEK293, His) is the recombinant Virus-derived West Nile Virus NS1 protein, expressed by HEK293 , with N-His labeled tag.

Species: Virus; Source: HEK293

Viral Proteins

/
HY-P7833 CD19 Protein, Cynomolgus/Rhesus Macaque (HEK293, Fc)
CD19 is a signaling component of the B-cell receptor complex that lowers the threshold for antigen-driven activation. CD19 Protein, Cynomolgus/Rhesus Macaque (HEK293, Fc) is the recombinant Rhesus Macaque-derived CD19 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Rhesus Macaque; Cynomolgus; Source: HEK293

CAR-T Related Proteins CD Antigens CD19 B Cell CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins

/
HY-P705605 MLK1 Protein, Human (Active, Biotinylated, sf9, His, Avi)

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Kinases Transferases (EC 2) Serine/Threonine Kinase Proteins TKL MLK

/
HY-P705995 MLK1 Protein, Human (Active, sf9, His-GST)

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Kinases Transferases (EC 2) TKL MLK

/
HY-P704441 CD19 Protein, Cynomolgus/Rhesus Macaque (CHO, hFc)
CD19 is a signaling component of the B-cell receptor complex that lowers the threshold for antigen-driven activation. CD19 Protein, Cynomolgus/Rhesus Macaque (CHO, hFc) is the recombinant rhesus macaque/cynomolgus-derived CD19 protein, expressed by CHO, with C-hFc labeled tag.

Species: Rhesus Macaque; Cynomolgus; Source: CHO

CAR-T Related Proteins CD Antigens CD19 B Cell CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins

/
HY-P704445 CD19 Protein, Human (CHO, His)
The CD19 protein is a B cell antigen receptor coreceptor that enhances downstream signaling pathways, lowers the activation threshold, and helps B cells respond to antigens. It activates phosphatidylinositol 3-kinase and mobilizes intracellular Ca(2+). CD19 Protein, Human (CHO, His) is the recombinant human-derived CD19 protein, expressed by CHO, with C-His labeled tag.

Species: Human; Source: CHO

CAR-T Related Proteins CD Antigens CD19 B Cell CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins

/
HY-P705110 CD19 Protein, Human (Biotinylated, HEK293, His-Avi)
The CD19 protein is a B cell antigen receptor coreceptor that enhances downstream signaling pathways, lowers the activation threshold, and helps B cells respond to antigens. It activates phosphatidylinositol 3-kinase and mobilizes intracellular Ca(2+). CD19, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived CD19 protein, expressed by HEK293, with C-Avi;C-hFc labeled tag.

Species: Human; Source: HEK293

CAR-T Related Proteins CD Antigens Biotinylated Proteins CD19 B Cell CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins

/
HY-P705413 CD19 Protein, Human (HEK293, mFc)
The CD19 protein is a B cell antigen receptor coreceptor that enhances downstream signaling pathways, lowers the activation threshold, and helps B cells respond to antigens. It activates phosphatidylinositol 3-kinase and mobilizes intracellular Ca(2+). CD19, Human (HEK293, mFc) is the recombinant human-derived CD19 protein, expressed by HEK293, with N-6*His labeled tag.

Species: Human; Source: HEK293

CAR-T Related Proteins CD Antigens CD19 B Cell CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins

/
HY-P706198 BZLF1 Protein, Epstein-Barr virus (HEK293, His)

Species: Virus; Source: E. coli

Viral Proteins

/
HY-P87753 Phospho-MLKL (Ser345) Antibody (YA7438)
Phospho-MLKL (Ser345) Antibody (YA7438) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to Phospho-MLKL (Ser345).

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Modification Specific Antibodies Primary Antibodies

/
HY-P80131 Fos B Antibody (YA431)
Fos B Antibody (YA431) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Fos B.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P85738 c-Fos Antibody (YA5430)
c-Fos Antibody (YA5430) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to c-Fos.

Host: Mouse; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Primary Antibodies

/
HY-P80446 CD19 Antibody (YA543)
CD19 Antibody (YA543) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD19.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P80597 CD19 Antibody (YA807)
CD19 Antibody (YA807) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD19.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P83063 TRAF4 Antibody (YA2808)
TRAF4 Antibody (YA2808) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TRAF4.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P86228 MLKL Antibody (YA5920)
MLKL Antibody (YA5920) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MLKL.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P87661 Fos B Antibody (YA7346)
Fos B Antibody (YA7346) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to Fos B.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81328 Switch Associated Protein 70 Antibody (YA1073)
Switch Associated Protein 70 Antibody (YA1073) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Switch Associated Protein 70.

Host: Mouse; Reactivity: Human, Mouse, Rat, Monkey

Monoclonal Antibodies Primary Antibodies

/
HY-P81328A Switch Associated Protein 70 Antibody (YA1073)(PBS only)
Switch Associated Protein 70 Antibody (YA1073) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Switch Associated Protein 70.

Host: Mouse; Reactivity: Human, Mouse, Rat, Monkey

Monoclonal Antibodies Primary Antibodies

/
HY-P85565 Switch Associated Protein 70 Antibody (YA5257)
Switch Associated Protein 70 Antibody (YA5257) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Switch Associated Protein 70.

Host: Mouse; Reactivity: Human, Mouse, Rat, Monkey

Monoclonal Antibodies Primary Antibodies

/
HY-P8F010A FITC-conjugated CD19 Antibody (4G7)
FITC-conjugated CD19 Antibody (4G7) is a Mouse-derived and FITC conjugated monoclonal antibody, targeting to CD19.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Conjugated Primary Antibodies Primary Antibodies

/
HY-P8F010C PE-conjugated CD19 Antibody (4G7)
PE-conjugated CD19 Antibody (4G7) is a Mouse-derived and PE conjugated monoclonal antibody, targeting to CD19.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Conjugated Primary Antibodies Primary Antibodies

/
HY-P8F010F PerCP-conjugated CD19 Antibody (4G7)
PerCP-conjugated CD19 Antibody (4G7) is a Mouse-derived and PerCP conjugated monoclonal antibody, targeting to CD19.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Conjugated Primary Antibodies Primary Antibodies

/
HY-P8F010I APC-conjugated CD19 Antibody (4G7)
APC-conjugated CD19 Antibody (4G7) is a Mouse-derived and APC conjugated monoclonal antibody, targeting to CD19.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Conjugated Primary Antibodies Primary Antibodies

/
HY-P8F058A FITC-conjugated CD19 Antibody (1D3)
FITC-conjugated CD19 Antibody (1D3) is a Rat-derived and FITC conjugated monoclonal antibody, targeting to CD19.

Host: Rat; Reactivity: Mouse

Monoclonal Antibodies Flow Cytometry Antibodies Conjugated Primary Antibodies Primary Antibodies

/
HY-P8F058C PE-conjugated CD19 Antibody (1D3)
PE-conjugated CD19 Antibody (1D3) is a Rat-derived and PE conjugated monoclonal antibody, targeting to CD19.

Host: Rat; Reactivity: Mouse

Monoclonal Antibodies Flow Cytometry Antibodies Conjugated Primary Antibodies Primary Antibodies

/
HY-P80597A CD19 Antibody (YA807)(PBS only)
CD19 Antibody (YA807) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD19.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P811298 G0S2 Antibody
G0S2 Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to G0S2.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-P86647 CD19 Antibody (YA6339)
CD19 Antibody (YA6339) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD19.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-K2034 OptiLNP Antibody-ctLNP RNA Transfection Reagent (Human Primary T Cells)

MCE OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) utilizes antibody-conjugated cell-targeted lipid nanoparticle (Cell-targeted Lipid Nanoparticle, ctLNP) technology and is specifically optimized for human primary T cells. It enables efficient and targeted RNA delivery, improving transfection efficiency in difficult-to-transfect primary T cells. The kit is ideally suited for applications including CAR-T and TCR-T cell engineering, cancer immunology research, immune cell engineering, and in vitro T cell functional studies.

Cell Biology Cell Culture Cell Transfection

/
HY-K6504 Human iPSC/ESC Cortical Brain Organoid Maturation Medium

MCE Human iPSC/ESC Cortical Brain Organoid Maturation Medium is a ready-to-use culture system specifically formulated for the long-term maintenance and maturation of cortical brain organoids. It serves as a seamless transition from the induction phase and supports the continued growth and functional development of the organoids. Upon switching PSC-derived cortical brain organoids to this medium, organoid viability and structural stability are markedly enhanced, enabling a robust and extended culture period of up to 180 d.

Cell Biology 3D Cell Culture PSC Induction Product Series

/

Keywords

CAR-T relapse | antigen escape | CD19 | T-cell exhaustion | lineage switch | CAR persistence